HUE033204T2 - Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére - Google Patents

Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére Download PDF

Info

Publication number
HUE033204T2
HUE033204T2 HUE11761051A HUE11761051A HUE033204T2 HU E033204 T2 HUE033204 T2 HU E033204T2 HU E11761051 A HUE11761051 A HU E11761051A HU E11761051 A HUE11761051 A HU E11761051A HU E033204 T2 HUE033204 T2 HU E033204T2
Authority
HU
Hungary
Prior art keywords
obb
fii
fibrinogen
blood
fviia
Prior art date
Application number
HUE11761051A
Other languages
English (en)
Inventor
Ann Lovgren
Kenny Hansson
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033204(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HUE033204T2 publication Critical patent/HUE033204T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4833Thrombin (3.4.21.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/363Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (5)

  1. Γ*Κϊι>»ΙΙΟΝΜ««*Η*\\ UH ÍOV\B«lF\MOKOfcA\t Μ>Μ*ίϊ\,Μ \ \-Η«,Ι ? s$On kOW^U^AHU Μ yV^/JFi ΟΟΟ ΚΛΗΟΝ,ΟίΚΗί Hl MOS' ί SÍI*· ΚΙ £Μ f XFRν |Mfcsi|^Í8» ifF8f pímíöfe S v Aivadáslíákm^k^HH, amely » köveítebk M«;y W§í áll: i; > kik vagy i "í i U i \ Μ X S í X UmS'Ci;,^ a\\V, S,ígV i.'! fibdm*gá« és Fii FVfla és. FX kíí?8kls^l|i:A ^y (4.j fibrtrsogén és Fék vagy vagv (F); tibisöpíi FH #S fVíU » í í s v V ., 1V „ s s SS·. H| i V ss * , s. s > i s JV Tk 5 V s ts í V ateknaáSü^. k \h V'aiiv vVss'V-yv^ag ,. m . k-A,!H \«k isO>whOO all {OFlLvsgy ('·) Fii FV Oá és FX konHFoaeióyy v agy (3? fsbrioogé» ás Fii FVUa es FX kombinációja, vagy (4 j Fibrinogen és Hl, vagy CH FH é? FViía, vagy (6! übrioogén. FH ás FVIH, ihi'«ulá$os kösgísiorásiiiva'· össreilíggb kávásodon bemossíáxilbsb sesfivsdb es8iö$bé8; á; maximáld, a:, HFksí dard,-ag íMCÍ » Í\oc':cjd't'0 ΙΗίνΒν alFaimaeVana
  2. 3. Aiv a kbvelkexdk bármelyikéből |!|; (í i Hi, vagy (2d Fii, F'V'iKt és FX kombinációja, vagy Hí íibrimígFicsk Ili FVíía és FX knmbbvklfjá, >a|iy (4) Ohrinogén és FH, vagy (S í Fii és FVÍks, vagy H5' ííbrmoa''8, i iiv. k\ lk5 hígaOv·* koagük'poS'avoi várnia >v Loosodob í om --10.Hars o-vased" 'cd v-ben s s,-Ό ,, κ- η-- Η Η ϊ csökkentésében Hnend aikaimaaáí ra.
  3. 4. AiVagg,,;faklor-kv ?e ie s. amtdy a kOveiXsabk bármely lkából áli (i,i Hi. vagy Hí i ii F\ ligás FX kombinációja, vagy Hí ftbrmogsm ex FH. FVHaéx FX konthrnóbíSfá sags O" oí"'í SvO>slH >,,vv (S> Hí és kVIlíg vagy léi bbHnogéo, Hí és FViia, blksltlsOx bssxHiSggi; fefessílöi::.i:te©^2^ssMn. i?|lgVs$&amp;:8: IÍ?s^!ÍMpÍí||s: >'vba.nb<n Mseik Hko.ío l\a' í 5. A?. M. >g«nvpo8tok· bJník'íyü^ szcTíiiíi »i\ndási&amp;l tor-kcf^éi. az m megHatároxott alkl!í$g$|.&amp;% :^§ sz Hl rhHt «* 1-tC* m#k*>l6mbaa bossioik
  4. 6, Ax |-5. i>><síϊv}>í>ísSisk bármelyike s»vsbál aivas&amp;ss faktorkcxeko. a.>: ο». megbatározott alkalmadra, a higuiáxos ks>sgsslefáiiávsb bss2®%gb Mrasssibb Κακοβϋ&amp;χρ jelelik Vérveszteséggel fógg 9¾ például MMxen beavstkossás kdrdb. seb-ésxe» beavaütnxá* ιϋ&amp;η vMfed vagy ptíMpastussv homon'hádávd bsvxeAiggöjdémbs vósv®M®sá|pb % Az Ml igénypontok kársnetyite sxetltó atkalmwásra* áboilsx Fik FVÍI&amp; vagy FX tü (slMl), tblombmáns FVíta (rhkVib? vagy rekombinám, IX (rhldO. 8 Αχ:;:Mí. ipán pontok bármelyike s^riml aiv-adásifaktor-kexeiév az őrt megbatározott aik&amp;Sma&amp;bm. ahol a fexelásí-e ssüi'dó emlős ftbtníog-.'okciocínirásc'tójáftak Némáimra kevesebb. mint mitaegy 2 y k keltebb, roM mintegy Ig4 keyssobfe, mim mls%y:l>d g- b kevesebb, mint mintegy 200 mgrdi, kevesebb, mint nüm<?£. ISO mg/db kevesebb, mid mintegy I<j0 mgM? vagy kevesebb, mim mmtegy Mi bt|/di: % Az i-k, lgd»^®»5töfe?%ár^IÍ5fe: saserinti aHad&amp;tiaMor-kexefcis ax ott meg&amp;asmwott aikaímaxástn, shoi &amp; károsodon herooMábs egy emlős beebtfi teljes véstérfe|ístásak spiMegy 10%-áosi nagyobb, mintegy .tÖ’Másvá! nagyobb, mintegy SÖ^ánál Hrgpbiy mmiegy őWv-gtsái :sagy«b% mtótogy 70%-áoá^ napobb, ív ,v.v 50V ,η,άΗοί. >o,*' , m v 'n M^ ;>· v<i''! ' >, -< 'v^ ük A 0. igénypont szermti stvud&amp;sitákfookezeiés az no mcKharitoísrU. ,»iksiötazSsr%:,aboI>» liipj^»s;:. ku&amp;gukspátb nomtovolémia viasxaáSlitáNifcól va&amp;\ h&amp;irwihm^jM8ÍM®mámö^miL·. U. Ax MC*. igénypontok bármelyik* semmis d vMá5Mktor4e,Mós sm ott snegteMrosod (bkaMMíMi, ah»! olyan menny Myben adunk be fibrkmngém, smHy «iegtxstfc a vét fibríöt^.fcoöceairáci^ának mimegy -Öi5 gA-tniniegy·1 §&amp;-mintegy 1,5 g.A vagy-mmtegy 2 mgd iíM* emeléséhez.
  5. 12. Ax HU. igénjpontok bánod) ike t-zerinti dvadássibktor-ke?®ies a? ott niegteüámeou atkaimaxasra, nhol o fibrinogen 12;5HÍÍ10 mg/kg doxixixiu boadotb JX Az M2. ípuypootok bámielyiks szeriníi <dv&amp;<tóij.irakrur*k«xeiéx az ott abo? ü.í atva:ias»Mn>r-kwekb; olyan dógixban beabotk smeiy mintegy 4(Msö ukiaMporocei cxkkkvob 3?. ;dvadás; (dot. .x;xd> mnm'gt W A «rm-A rmh a ma'.nwK aK.Kkk'od.odx«\-f. oa v.^ a Oo.ake, man k-pbtbb UX óráig íKsroorbxán koasniávk; fennmaradásár eredmssjyezi. i4 Αϋ Fi.5 tM>oo{.xokok hárbndspo ^xibu. oXadasdakiui.koruké ac· on (OoH'oíoíoxoís ,d ό .λ ; alsói |κ aiyidiáailaktof-kexolós (iy fíí.tFVlbí by bX kooiblf.áoiéá&amp; vagy f.>) Ft!. FVÍfa óv i'X kombinslcitita dH.oogvr.oob ev .not .to t H vo i'X bo kyak'^b ; '-Hi .uo>oK«> l robots :15. Az Mo. ígéovposHok bóstuolyikv ssrlstiFskvadasibiktor-keioid;; a? ou usoghosároxot; atkaimazsism. :íÉöí;^:áivadávitaktOí-Wela§ ü> pll vagy (4) kbnssogáo Hl-
HUE11761051A 2010-10-06 2011-09-19 Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére HUE033204T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
HUE033204T2 true HUE033204T2 (hu) 2017-11-28

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11761051A HUE033204T2 (hu) 2010-10-06 2011-09-19 Faktor II önmagában vagy további faktorral kombinálva, hígulásos koagulopátiával összefüggõ károsodott hemosztázis kezelésére

Country Status (16)

Country Link
US (1) US9433664B2 (hu)
EP (1) EP2624859B1 (hu)
JP (1) JP6000259B2 (hu)
KR (1) KR20130136988A (hu)
CN (1) CN103221061A (hu)
AU (1) AU2011313505B2 (hu)
BR (1) BR112013008034A2 (hu)
CA (1) CA2812888A1 (hu)
DK (1) DK2624859T3 (hu)
ES (1) ES2625153T3 (hu)
HU (1) HUE033204T2 (hu)
MX (1) MX343784B (hu)
PL (1) PL2624859T3 (hu)
RU (1) RU2606155C2 (hu)
SG (2) SG10201508159SA (hu)
WO (1) WO2012045569A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221061A (zh) 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原
IL230150A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
EP3579857B1 (en) * 2017-02-09 2022-04-06 CSL Behring GmbH A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686385B2 (ja) 1980-01-28 1994-11-02 バクスタ−、インタ−ナショナル、インコ−ポレイテッド 活性プロトロンビン複合体組成物およびその製造方法
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DK0796623T3 (da) 1996-03-20 2005-08-01 Baxter Ag Farmaceutisk præparat til behandling af blodkoagulationslidelser
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
CA2437015A1 (en) 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
KR20040015821A (ko) * 2001-07-20 2004-02-19 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드와 인자 ⅹⅰ폴리펩티드를 포함하는약학적 조성물
US20040101546A1 (en) 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
NZ541489A (en) 2002-12-31 2011-06-30 Marinepolymer Tech Inc Topically applied vasoconstrictor for treatment in cardic catheterization complications
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005117912A1 (en) 2004-05-27 2005-12-15 Avigen, Inc. Methods for treating bleeding disorders using sulfated polysaccharides
US20080188400A1 (en) 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2009528843A (ja) * 2006-03-06 2009-08-13 ヒューマジーン・インコーポレイテッド 組換えヒトトロンビンおよびフィブリノゲンの調製法
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
WO2008051513A2 (en) 2006-10-23 2008-05-02 Allan Pronovost Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
WO2008121330A1 (en) 2007-03-30 2008-10-09 Thrombodyne, Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
UA101155C2 (ru) 2007-04-13 2013-03-11 Каталист Байосайенс, Инк. Модифицированный полипептид фактора vii (fvii) и его применение
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
CA2740079A1 (en) 2008-10-08 2010-04-15 Thrombodyne, Inc. Methods of making concentrated fibrinogen- and platelet-containing compositions
CN103221061A (zh) 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原

Also Published As

Publication number Publication date
MX2013003715A (es) 2013-09-26
AU2011313505B2 (en) 2015-09-17
KR20130136988A (ko) 2013-12-13
WO2012045569A9 (en) 2016-01-07
RU2013120033A (ru) 2014-11-20
US20130280236A1 (en) 2013-10-24
PL2624859T3 (pl) 2017-09-29
DK2624859T3 (en) 2017-06-06
ES2625153T3 (es) 2017-07-18
CN103221061A (zh) 2013-07-24
EP2624859A1 (en) 2013-08-14
RU2606155C2 (ru) 2017-01-10
BR112013008034A2 (pt) 2016-06-14
JP2013538863A (ja) 2013-10-17
WO2012045569A1 (en) 2012-04-12
EP2624859B1 (en) 2017-03-01
SG10201508159SA (en) 2015-10-29
CA2812888A1 (en) 2012-04-12
US9433664B2 (en) 2016-09-06
MX343784B (es) 2016-11-23
AU2011313505A1 (en) 2013-04-11
SG188639A1 (en) 2013-05-31
JP6000259B2 (ja) 2016-09-28

Similar Documents

Publication Publication Date Title
Moore et al. Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography?
ERIKSEN et al. Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy
Fries et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy—a porcine model
Remuzzi et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.
Dickneite et al. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P)
Mitterlechner et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model
Solomon et al. Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery
Schulman Pharmacologic tools to reduce bleeding in surgery
JPS58500994A (ja) 止血用医薬組成物
ES2230624T3 (es) Composicion farmaceutica que comprende un compuesto que tiene actividad anti-xa y un compuesto antagonista de la agregacion plaquetaria.
Honickel et al. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model
Woessner et al. Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study
US20100279939A1 (en) Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders
EP2624859B1 (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
CN102088999A (zh) 用于治疗凝血细胞抑制剂诱导的凝血病的血管假性血友病因子或因子viii和血管假性血友病因子
Kalbhenn et al. Bleeding during veno-venous ECMO: prevention and treatment
Rogers et al. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
Favaloro et al. Editorial compilation X
JP2012519674A (ja) フィブリノーゲンの新規な使用
CN110114074A (zh) 用于治疗或预防出血的凝血因子替代产品
Zhao et al. Efficacy of erythropoietin combined with tranexamic acid in reducing perioperative blood loss and blood transfusion rate in elderly patients with femoral intertrochanteric fractures
Bauer et al. Monitoring of heparin therapy and establishment of an optimal therapy scheme for thrombosis prophylaxis in a pig model for human catheter interventions
Arshad Pathophysiology and management of hemostatic alterations in cirrhosis and liver transplantation
Parameswaran et al. The use of recombinant factor VIIa in gastrointestinal bleeding
Maxwell et al. Motoyama & Davis: Smith's Anesthesia for Infants and Children